Synlogic stock.
Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November.
Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Dec 15, 2022 · Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. First Quarter 2023 Financial Results. As of March 31, 2023, Synlogic had cash, cash equivalents and short-term investments of $57.4 million. Revenue was $0.2 million for each of the three months ...CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...
SYBX Stock Summary. SYNLOGIC INC's market capitalization of $11,982,884 is ahead of only 7.07% of US-listed equities. As for revenue growth, note that SYBX's revenue has grown -47.85% over the past 12 months; that beats the revenue growth of merely 5.27% of US companies in our set. In terms of volatility of its share price, SYBX is more ...Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.
٣١/٠١/٢٠١٨ ... Was this some sort of “pivot”? Turns out that it's actually a secondary offering, not an IPO, and it is now an entirely new company as a result ...
CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...2 equities research analysts have issued twelve-month price targets for Synlogic's shares. Their SYBX share price targets range from $75.00 to $90.00. On average, they anticipate the company's share price to reach $82.50 in the next year. This suggests a possible upside of 3,351.9% from the stock's current price.INMB stock currently trades for $7.80 and reached a 52-week high of $11.78 while carrying an average target stock price of $18.00. Synlogic (SYBX) Biotechnology stocks, biomedical stocks.Continue Reading. September 28, 2023. Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism. Continue Reading. September 27, 2023. Synlogic Announces Reverse Stock Split. Continue Reading. September 21, 2023. Synlogic to Participate in Chardan’s Genetic Medicines Conference.
May 4, 2023 · Synlogic, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...
Get Synlogic Inc (SYBX.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Synlogic, Inc. (SYBX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 1.8499 -0.0201 (-1.07%)Third Quarter 2022 Financial Results. As of September 30, 2022, Synlogic had cash, cash equivalents and short-term investments of $91.7 million. Revenue for the three months ended September 30, 2022 was $0.7 million compared to $0.9 million for the corresponding period in 2021. Revenue in both periods was associated with the ongoing research ...Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Synlogic Inc stock performance at a glance. Check Synlogic Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and …Chardan Capital currently has a “Buy” rating and a $90.00 target price on the stock. The consensus estimate for Synlogic’s current full-year earnings is ($6.25) per share. Chardan Capital also issued estimates for Synlogic’s FY2024 earnings at ($3.87) EPS. Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 target ...
Real stock prices are not the same as the last traded stock price. Real stock prices are adjustments to closing stock prices. The adjustments are used in a variety of ways, including dividends, the range of prices and the closing price of t...Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic ...Concurrently with the execution of the Merger Agreement, certain officers, directors and stockholders of Mirna holding approximately 32% of the outstanding Mirna common stock and certain officers, directors and stockholders of Synlogic holding approximately 84% of the Synlogic capital stock (giving effect to Synlogic’s recent Series C financing) have …Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU). “We are …
Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Synlogic, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share data) June 30, 2023 . December 31, 2022. Assets . Cash, cash equivalents & marketable securities
Apr 25, 2023 · In discussing Synlogic (NASDAQ: SYBX) stock, let’s begin with the upside because it’s substantial. SYBX shares carry an average target price of $7.17 yet trade for $0.65. They are therefore a ... Synlogic Revenues and Earnings Beat Expectations. Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 1.1%. Looking ahead, revenue is forecast ...Mirna Therapeutics Inc (ZB_23894470.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Mirna Therapeutics Inc | Nasdaq: | Nasdaq. ... Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, …The first big announcement that META stock fans will want to note is details on the Meta Quest 3. This is the company’s VR headset that offers 10x the number of pixels as the Meta Quest 2 for $500.CAMBRIDGE, Mass., Sept. 20, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive data from clinical studies evaluating both SYNB1618 and SYNB1934, investigational Synthetic Biotic™ medicines for the treatment …Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.View live Synlogic, Inc. chart to track its stock's price action. Find market predictions, SYBX financials and market news.INMB stock currently trades for $7.80 and reached a 52-week high of $11.78 while carrying an average target stock price of $18.00. Synlogic (SYBX) Biotechnology stocks, biomedical stocks.
View Your Watchlist. Stock analysis for Synlogic Inc (SYBX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and …
MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept. Apr. 27. MT. Chardan Adjusts Price Target on Synlogic to $5.50 From $7, Keeps Buy Rating. Mar. 30. MT. Synlogic Rating Maintained at Buy But Price Target Lowered to $5.50 at Chardan Due to 'Higher Projected Future Share Count'. Mar. 30.
SYBX Stock Performance Soars with 1,939.98% Increase: Analysts Predict Strong Growth for Synlogic Inc. SYBX stock had a significant performance on September 27, 2023. The 12-month price forecasts from three analysts for Synlogic Inc had a median target of $5.00, with a high estimate of $6.00 and a low estimate of $4.00.Nov 29, 2023 · 2 equities research analysts have issued twelve-month price targets for Synlogic's shares. Their SYBX share price targets range from $75.00 to $90.00. On average, they anticipate the company's share price to reach $82.50 in the next year. This suggests a possible upside of 3,351.9% from the stock's current price. Sep 28, 2023 · Continue Reading. September 28, 2023. Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism. Continue Reading. September 27, 2023. Synlogic Announces Reverse Stock Split. Continue Reading. September 21, 2023. Synlogic to Participate in Chardan’s Genetic Medicines Conference. ١٣/٠٦/٢٠١٩ ... ... shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The ...A rating of 71 puts Synlogic Inc near the top of the Biotechnology industry according to InvestorsObserver. Synlogic Inc's score of 71 means it scores higher than 71% of stocks in the industry. Synlogic Inc also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 17 out of the 148 industries.Second Quarter 2023 Financial Results and Financial Outlook. As of June 30, 2023, Synlogic had cash and cash equivalents of $46.3 million. Revenue for the three months ended June 30, 2023 was $35 thousand compared to $152 thousand for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research ...Synlogic Inc stocks price quote with latest real-time prices, charts, financials, latest news, ... Do the numbers hold clues to what lies ahead for the stock? SYBX: 0.8376 (-3.60%) ROIV: 5.14 (-2.10%) Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks PR Newswire - Thu Aug 11, 6:05AM CDTSynlogic’s pipeline is fueled by its Synthetic Biotic platform, which applies precision engineering to well-characterized probiotics. This creates GI-restricted, oral medicines designed to consume or modify disease-specific metabolites – an approach well suited for diseases such as PKU and HCU, both inborn errors of metabolism, as well as others in …Synlogic trades on the NASDAQ stock market under the symbol SYBX. What is Synlogic stock price doing today? As of November 24, 2023, SYBX stock price declined to $2.00 with 12,590 million shares trading.The last twelve months weren't great for Synlogic shares, which cost holders 12%, while the market was up about 15%. Of course the long term matters more than the short term, and even great stocks ...
Synlogic, Inc. CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed ...Synlogic, Inc. CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S ...The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Science 37's Metasite ...Instagram:https://instagram. meridian bioscience stockwhich penny stocks to buy nowprop trading companiesdoes medicaid cover braces adults Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...Formed in 2019, the Synlogic - Ginkgo collaboration is a five year, $30M strategic platform collaboration which accelerates expansion and development of Synlogic's pipeline of Synthetic Biotic ... spacex stocksexelisis Figure 5: Synlogic Stock Chart (source: finviz) Thus, Synlogic looks like a good value at current levels, although, obviously, still a high-risk investment due to the early stages of its assets.Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a form of precision biological engineering, with principles of traditional drug development to design medicines for diseases that are in need of new approaches. The result is a robust engine that can create these potential medicines, called Synthetic ... nel hydrogen stock Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis.Mar 24, 2021 · CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low calcium diet were treated with multiple ascending doses of SYNB8802.